tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
MoonLake Immunotherapeutics price target raised to $30 from $25 at Oppenheimer
PremiumThe FlyMoonLake Immunotherapeutics price target raised to $30 from $25 at Oppenheimer
1M ago
MoonLake Immunotherapeutics price target raised to $8 from $7 at Goldman Sachs
Premium
The Fly
MoonLake Immunotherapeutics price target raised to $8 from $7 at Goldman Sachs
1M ago
MoonLake Immunotherapeutics Announces $75M Share Offering
Premium
Company Announcements
MoonLake Immunotherapeutics Announces $75M Share Offering
1M ago
MoonLake Immunotherapeutics Advances with Promising Sonelokimab Study in Adolescents
PremiumCompany AnnouncementsMoonLake Immunotherapeutics Advances with Promising Sonelokimab Study in Adolescents
2M ago
Moonlake Immunotherapeutics Advances in Hidradenitis Suppurativa Treatment with Sonelokimab Study
Premium
Company Announcements
Moonlake Immunotherapeutics Advances in Hidradenitis Suppurativa Treatment with Sonelokimab Study
2M ago
MoonLake’s Promising Phase 3 Study on Sonelokimab for Psoriatic Arthritis
Premium
Company Announcements
MoonLake’s Promising Phase 3 Study on Sonelokimab for Psoriatic Arthritis
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100